ICBCCS SSE STAR Biology and Medicine ETF

Sci-Tech Innovation Board Companies Projected Earnings Growth in 2025, Several Companies Expected to 'Delist'

BeiGene Reports First Profit in 2025 with Record Sales

Xiong Jun Increases Stake in Junshi Biosciences to 8.56%

Janssen Biotech Chairman Xiong Jun Plans to Increase Holdings in Company Shares

JSL Bio's Toripalimab Injection Application for 12 Indications in Cancer Treatment Accepted for Review

Junshi Biosciences to Release FY2025 Earnings on March 13 After-Market (BJT), Forecast Revenue CNY 2.519 B, EPS CNY -0.84

CICC Publishes Report on Biogen's FY2022 Revenue Meeting Expectations

JPMorgan Adjusts Biogen's Target Price

BOA Raises Price Target for BeiGene and Sees Strong 2026 Prospects

BeiGene Reports 2025 Earnings, Transitions to Profitability but Sees Stock Decline

Junshi Biosciences Reports 2025 Financials: Revenue Up 28.2%, Net Loss Narrows

Guotai Junan and DBS Maintain Buy Rating on BeiGene

BeiGene Achieves First Yearly Profit but Faces Slowing Growth

Bailitianteng Sees Significant Revenue and Profit Decline in 2025 with Increased R&D Spending

Juno Biotech Reports a 28.23% YoY Increase in Operating Revenue in 2025

MGI released FY2025 earnings on February 27 During-Market (BJT), actual revenue CNY 2.78 B (forecast CNY 2.937 B), actual EPS CNY -0.58 (forecast CNY -0.1864)

MGI released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 910.7 M (forecast CNY 1.129 B), actual EPS CNY -0.2953 (forecast CNY -0.0146)

Zelgen released FY2025 Annual Earnings on February 27 During-Market (BJT), Actual Revenue CNY 812.73 M (Forecast CNY 843.69 M), Actual EPS CNY -0.61 (Forecast CNY -0.3333)

Zelgen released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 219.29 M, actual EPS CNY -0.2658

588250

589720

516500

159837

512290

159849

588860

588130

Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor

marketscreener

Penghua SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

SINO BIOPHARM

China Merchants CSI Biotechnology Theme ETF

SIHUAN PHARM PREF OFFER

China Universal 800 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor

159316

159570

562050

159506

512010

159102

520690

560600

516820

159859

159615

510660

Shares of Pharmaron Beijing surged over 13% after announcing a partnership with Eli Lilly, which includes a $200 million investment to manufacture a diabetes and weight-loss drug, orforglipron. The stock closed 8.4% higher, marking its largest single-day rise since September. Eli Lilly aims to gain regulatory approval for the drug in over 40 countries, with the partnership seen as a significant milestone for Pharmaron's business. Eli Lilly is also expanding its supply chain capacity in China, with nearly $6 billion in investments in the country.

E Fund Hang Seng SCHK Innovative Drug ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Penghua CSI HK Connect Health Care Composite ETF

Minsheng Royal CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

China Southern Hang Seng Biotech ETF(QDII)

Pharmaron

Eli Lilly

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Pharmaron Beijing Shares Jump After Eli Lilly Pledges $200 Million Investment in Partnership

SinoMab BioScience Ltd. has terminated a 20-year lease for the SinoMab Building at Haiyao Industry Park in Haikou, effective March 12, 2026. This decision aligns with the company's transition to a light-asset manufacturing model, outsourcing production for drug candidates to contract manufacturers. The lease termination will lead to the derecognition of a right-of-use asset valued at approximately RMB35.8 million and is classified as a connected transaction under Hong Kong listing rules.

PUBT

SINOMAB BIO-B

SinoMab BioScience terminates 20-year lease for Haikou Industry Park property

Goldman Sachs gives Pharmaron a "Buy" rating with a target price of 30.7 yuan. Pharmaron has reached a collaboration with Eli Lilly, which will invest 200 million USD to support the supply of Orforglipron in China. Eli Lilly plans to invest 3 billion USD over the next decade to expand its supply chain capacity in China. Goldman Sachs believes this collaboration reflects Eli Lilly's confidence in the Chinese market and expects Pharmaron to receive a positive market response

AASTOCKS

PHARMARON

Goldman Sachs gives Pharmaron a "Buy" rating with a target price of 30.7 yuan

Multinational pharmaceutical companies are changing their roles by authorizing local enterprises to distribute products, forming a deeply symbiotic cooperation model. MNCs provide R&D technology and products, while Chinese companies are responsible for nationwide logistics and marketing. This model has evolved from simple distribution to strategic cooperation based on trust and resource exchange, promoting growth for both parties. The collaboration case between Roche and CHINARES PHARMA demonstrates the success of this model, as both sides maximize market potential through resource complementarity

腾讯新闻 - 财经

CHINARES PHARMA

Hwabao WP CSI Medical Service ETF

Bosera Hang Seng Health Care ETF(QDII)

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

New Competitive Model: Foreign Companies Produce Products, Local Enterprises Provide Channels

Sino Biopharmaceutical says TQB3205 pan-Kras inhibitor receives NMPA clinical trial approval

Sino Biopharmaceutical says TQB3205 pan-Kras inhibitor receives NMPA clinical trial approval

IBBQ

Isofol Secures Stakeholder Support Covering 42% of Upcoming TO1 Warrant Exercise

Tip Ranks

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Isofol Secures Stakeholder Support Covering 42% of Upcoming TO1 Warrant Exercise

688235

06160

688256

Recently, companies such as Cambricon and BeOne Medicines released performance reports, all achieving a turnaround to profitability in annual net profit attributable to shareholders, meeting the criteria for removal from the STAR Market's growth tier. These companies are expected to become the first batch of enterprises removed due to meeting performance standards. The growth tier of the STAR Market primarily serves unprofitable technology companies and currently includes 39 companies, mainly concentrated in the fields of next-generation information technology and biomedicine. According to relevant regulations, removal requires meeting conditions for net profit and operating revenue

BeOne Medicines

BEONE MEDICINES

Cambricon

Performance report brings good news! Cambricon, BeOne Medicines, and several other companies may exit the STAR Market growth tier

Everest Medicines has launched VELSIPITY' (etrasimod arginine tablets) in Mainland China, issuing the first prescription at The First Affiliated Hospital of Sun Yat-sen University. The drug aims to address the unmet needs of patients with moderately to severely active ulcerative colitis (UC). VELSIPITY' has been prescribed in eight hospitals across major cities, reflecting strong clinical demand. Approved by China's NMPA in February, the drug is expected to significantly impact the growing IBD treatment market in China, projected to exceed RMB 10 billion by 2030. Clinical studies show VELSIPITY' offers rapid action, long-lasting remission, and a favorable safety profile.

Asian Corporate Newswire

Yinhua CNI HK Connect Innovative Drugs ETF

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis

Sino Biopharmaceutical Unit Gets China Nod for Tumor Drug Trial

Sino Biopharmaceutical Unit Gets China Nod for Tumor Drug Trial

Biome Analytics has unveiled two new cardiovascular administrator productivity tools - Biome Strategy Board™ and Biome Presentation Builder™. These innovative solutions aim to enhance efficiency by removing manual reporting processes, simplifying initiative tracking, and introducing real-time accountability within cardiovascular service lines. Healthcare administrators and hospitals are currently facing challenges due to operating at full capacity, with the manual reporting burden continuously increasing.

Unusual Whales

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

BlackRock, Inc.

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VG Health

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Pharma

Biome Analytics Launches First-of-Its-Kind Cardiovascular Productivity Tools to Transform Healthcare Reporting and Accountability

Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results

SKB BIO-B

KELUN PHARMA

Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results

Beijing Biostar Sets March Board Meeting to Approve 2025 Results and Mull Dividend

Beijing Biostar Sets March Board Meeting to Approve 2025 Results and Mull Dividend

HSDT

CS精准医

DFDVW

Cathie Wood's ARK Invest ETFs made significant purchases in CRISPR Therapeutics (CRSP) and 3iQ SOLANA STAKING ETF (TSE:SOLQ) on March 10, capitalizing on recent dips. ARK bought 280,609 shares of CRSP for approximately $14.82 million after a 10.2% drop due to a $350 million private offering announcement. The stock has a Moderate Buy consensus rating with a target price of $70.21, suggesting a 33% upside. ARK also sold shares in 10X Genomics and Teradyne, trimming its positions in other firms.

- ARK Invest ETFs made strategic purchases in biotech and cryptocurrency sectors on March 10, focusing on CRISPR Therapeutics, 3iQ SOLANA STAKING ETF, and GeneDx Holdings.  
- The firm sold shares in 10X Genomics, Teradyne, and Brera Holdings, with significant offloads totaling approximately $8.07 million.  
- ARK's acquisition of CRISPR follows a 10.2% price drop related to a $350 million private offering, which aims to fund general corporate needs, with a current average price target suggesting a potential 33% upside.

ICBCCS SSE STAR Biology and Medicine ETF(588860.SH)

Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor

Pharmaron Beijing Shares Jump After Eli Lilly Pledges $200 Million Investment in Partnership

SinoMab BioScience terminates 20-year lease for Haikou Industry Park property

Goldman Sachs gives Pharmaron a "Buy" rating with a target price of 30.7 yuan

New Competitive Model: Foreign Companies Produce Products, Local Enterprises Provide Channels